BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22217531)

  • 1. Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.
    Wagner D; Amrein K; Dimai HP; Kniepeiss D; Tscheliessnigg KH; Kornprat P; Dobnig H; Pieber T; Fahrleitner-Pammer A
    Transplantation; 2012 Feb; 93(3):331-6. PubMed ID: 22217531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study.
    Misof BM; Patsch JM; Roschger P; Muschitz C; Gamsjaeger S; Paschalis EP; Prokop E; Klaushofer K; Pietschmann P; Resch H
    J Bone Miner Res; 2014 Feb; 29(2):440-9. PubMed ID: 23832525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
    Fahrleitner-Pammer A; Piswanger-Soelkner JC; Pieber TR; Obermayer-Pietsch BM; Pilz S; Dimai HP; Prenner G; Tscheliessnigg KH; Hauge E; Portugaller RH; Dobnig H
    J Bone Miner Res; 2009 Jul; 24(7):1335-44. PubMed ID: 19257824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of osteoporosis after liver transplantation with ibandronate.
    Kaemmerer D; Lehmann G; Wolf G; Settmacher U; Hommann M
    Transpl Int; 2010 Jul; 23(7):753-9. PubMed ID: 20158691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
    Shane E; Rodino MA; McMahon DJ; Addesso V; Staron RB; Seibel MJ; Mancini D; Michler RE; Lo SH
    J Heart Lung Transplant; 1998 Nov; 17(11):1089-96. PubMed ID: 9855448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.
    Anagnostis P; Vyzantiadis TA; Charizopoulou M; Adamidou F; Karras S; Goulis DG; Karagiannis A; Garipidou V; Vakalopoulou S
    Thromb Haemost; 2013 Aug; 110(2):257-63. PubMed ID: 23740140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.
    Kaemmerer D; Schmidt B; Lehmann G; Wolf G; Hommann M; Settmacher U
    Transplant Proc; 2012 Jun; 44(5):1362-7. PubMed ID: 22664016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate prevents further bone loss in renal transplant recipients.
    Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
    J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.
    Sambrook P; Cranney A; Adachi JD
    Curr Med Res Opin; 2010 Mar; 26(3):599-604. PubMed ID: 20055751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
    Klaus J; Reinshagen M; Herdt K; Adler G; von Boyen GB; von Tirpitz C
    J Gastrointestin Liver Dis; 2011 Jun; 20(2):141-8. PubMed ID: 21725510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study.
    Ebeling PR; Wark JD; Yeung S; Poon C; Salehi N; Nicholson GC; Kotowicz MA
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4098-103. PubMed ID: 11549632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
    Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
    J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta.
    Li M; Xia WB; Xing XP; Yu W; Hu YY; Jiang Y; Wang O; Liu HJ; Han LW; Meng XW; Xu L
    Chin Med J (Engl); 2011 Oct; 124(19):3049-53. PubMed ID: 22040553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis].
    Ikeda K; Fukagawa M
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664
    [No Abstract]   [Full Text] [Related]  

  • 19. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation.
    Smerud KT; Dolgos S; Olsen IC; Åsberg A; Sagedal S; Reisæter AV; Midtvedt K; Pfeffer P; Ueland T; Godang K; Bollerslev J; Hartmann A
    Am J Transplant; 2012 Dec; 12(12):3316-25. PubMed ID: 22946930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.